Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.
Security Error: PDF files must be hosted on the same domain as this site.
PDF is hosted on: https://www.pharmacytimes.com but this site is: https://www.certara.com
